

**AMENDED VERSION**

**IN THE CLAIMS:**

1. (Currently Amended) A method for unblocking immunization at a regional lymph node by:  
  
    promoting differentiation and maturation of immature dendritic cells in a regional lymph node and;  
  
    allowing presentation by resulting mature dendritic cells of antigen to T-cells to gain immunization of the T-cells to the antigen.
2. (Original) A method according to claim 1, wherein said promoting step is further defined as administering a natural cytokine mixture (NCM) perilymphatically into lymphatics that drain into lymph nodes regional to a lesion to be treated.
3. (Original) A method according to claim 2, wherein the lesion is cancerous or an other persistent lesion.
4. (Original) A method according to claim 3, wherein the presented lesion is infectious.
5. (Original) A method according to claim 1, wherein the antigen is an endogenous antigen.
6. (Original) A method according to claim 1, wherein the antigen is an exogenous antigen.
7. (Original) A method according to claim 2 wherein said administering step is further defined as injecting the NCM perilymphatically,

intralymphatically, intranodally, intrasplenically, subcutaneously, intramuscularly or intracutaneously.

Claim 8. (Withdrawn)

9. (Currently Amended) A method according to claim 72, wherein said administering step is further defined as administering an NCM including IL-1, IL-2, IL-6, IL-8,  $\delta$ IFN and  $\text{TNF}\alpha$ .

Claims 10-14 (Withdrawn)

15. (Currently Amended) A method according to claim 49, wherein said administering step ~~including~~includes administering about 150-600 units of IL-2 per injection ~~in~~ of the NCM.

16. (Currently Amended) A method according to claim 11, wherein said ~~blocking and inducing~~ unblocking steps are further defined as codelivering cyclophosphamide and a nonsteroidal anti-inflammatory drug (NSAID).

Claims 17-21. (Withdrawn)

22. (Currently Amended) A method according to claim 21, wherein the NSAID is selected from the group including INDOMETHACIN, IBUPROFEN, VIOXX, CELEBREX and other related compounds.

Claims 23-29. (Withdrawn)

Restriction to one of the following Groups was required under 35 USC

§121:

- I. Claims 1-7, drawn to a method for unblocking immunization, classified in class 424, subclass 93.7.
- II. Claims 8-16, drawn to a method of inducing immunization, classified in class 424, subclass 184.1.
- III. Claims 17-22, drawn to a method for treating cancer, classified in class 424, subclass 85.1.
- IV. Claims 23-28, drawn to a method of vaccine immunotherapy, classified in class 435, subclass 325.
- V. Claim 29, drawn to a method of treating lymphocytopenia, classified in class 424, subclass 85.1.

Applicant provisionally elects Group 1, claims 1-7 for prosecution purposes, with traverse. Applicant has amended claims 9, 15, 16, and 22 to ultimately depend on the claims of elected Group 1. Claim 22 depends on amended claim 16. Applicant hereby conditionally withdraws claims 8, 10-14, 17-21, and 23-29 from prosecution, without prejudice, and requests reconsideration of the restriction requirement.

Applicant traverses the restriction requirement based on the following grounds. It is respectfully submitted that the restriction requirement practice was established to promote efficiency of prosecution in the Patent Office. The five groups of claims relate to immunotherapy treatment and moreover four of the groups are classified in the same class, 424. Since there is a great amount of cross-classification amongst the subclasses in this class, it is respectfully submitted that examination of all of the claims in a single application would be efficient, thereby promoting the grounds for the establishment of the restriction requirement practice. Hence, it is respectfully submitted that restriction should not be required and that Applicant has traversed the restriction requirement.


However, as stated above, Applicant elects the claims of Group 1 and provisionally withdraws claims 8, 10-14, 17-21, and 23-29, without prejudice, pending reconsideration of the restriction requirement.

The Commissioner is authorized to charge any fee or credit any overpayment in connection with this communication to our Deposit Account No. 11-1449.

The application is now in condition for allowance, which allowance is respectfully solicited.

Respectfully submitted,

KOHN & ASSOCIATES, PLLC




Kenneth I. Kohn, Reg. No. 30,955  
30500 Northwestern Highway  
Suite 410  
Farmington Hills, Michigan 48334  
(248) 539-5050

Dated: January 6, 2004

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

Express Mail Mailing Label No.: EV 306 557 104 US  
Date of Deposit: January 6, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Mail Stop: Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Connie Herty